ClinConnect ClinConnect Logo
Search / Trial NCT07037810

Compare Multiple Daily Injections With Carbohydrate Counting or With Simplified Qualitative Meal-Size Estimation in Type 1 Diabetes

Launched by DASMAN DIABETES INSTITUTE · Jun 17, 2025

Trial Information

Current as of July 09, 2025

Enrolling by invitation

Keywords

Type 1 Diabetes Carbohydrate Counting Clinical Trial

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Males and females ≥ 21 years of age.
  • 2. Clinical diagnosis of T1D for at least 12 months. The diagnosis of T1D is based on the investigator's judgment; C-peptide level and antibody determinations are not needed.
  • 3. On MDI therapy.
  • 4. Previously trained to count carbohydrates through a structured education program or known to perform carbohydrate counting by their educator/ dietitian.
  • 5. Baseline HbA1c value ≥ 7.5% and \< 11% (up to 7 days before or after screening)
  • Exclusion Criteria:
  • 1. Serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.
  • 2. Failure to comply with the study protocol or with team's recommendations.
  • 3. Injection of isophane insulin (NPH) or any intermediate-acting insulin.
  • 4. More than 1 slow-acting injection and unwilling to switch to once a day for the study
  • 5. Current or ≤ 1 month use of other antihyperglycemic agents (SGLT2, GLP-1, Metformin, Acarbose, etc.).
  • 6. Pregnancy.
  • 7. Severe hypoglycemic episode within one month of admission.
  • 8. Severe diabetic ketoacidosis episode within one month of admission.
  • 9. Clinically significant nephropathy, neuropathy, or retinopathy as judged by the investigator.
  • 10. Conditions that may interfere with accurate HbA1c levels: clinically significant anemia, hemoglobinopathy, or a recent blood transfusion as judged by the investigator.

About Dasman Diabetes Institute

Dasman Diabetes Institute (DDI) is a leading research and clinical organization dedicated to advancing diabetes care and management through innovative research, education, and community outreach. Established to address the growing prevalence of diabetes, DDI focuses on conducting high-quality clinical trials aimed at developing effective prevention and treatment strategies. The institute collaborates with local and international partners to enhance understanding of diabetes and its complications, fostering a multidisciplinary approach that integrates clinical practice with cutting-edge research. With a commitment to improving patient outcomes, DDI serves as a vital resource for healthcare professionals, researchers, and individuals affected by diabetes.

Locations

Kuwait City, , Kuwait

Patients applied

0 patients applied

Trial Officials

Ebaa Al Ozairi, MD

Principal Investigator

Dasman Diabetes Institute

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported